We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Regenacy Pharmaceuticals announced the issuance of U.S. Patent No. 10,040,769 covering the use of ricolinostat (ACY-1215) for the treatment of diabetic peripheral neuropathy (DPN). Ricolinostat is an oral, selective inhibitor of the microtubule modifying